|
|
| Panbio Limited |
|
|
Established in 1988 and listed on the Australian Stock Exchange in 2001, Panbio Limited is an Australian-based international diagnostics company. With a mission of 'better tests for more people', the company develops, manufactures and markets innovative diagnostic tests to aid in the diagnosis of infectious diseases.
With a product portfolio covering over 58 infectious diseases, the company supports pathology laboratories and physicians in Australia, Asia, the Americas, Europe, the Middle East and Africa.
Panbio’s products are sold directly in Australia, the United States and through a network of distributors in Asia, Europe, the Middle East and Africa. Panbio is looking to expand its global distribution network in new markets.
Panbio’s range of technical platforms includes enzyme-linked immunosorbent assay (ELISA), indirect fluorescent antibody test (IFA) and rapid lateral flow devices. Across these platforms Panbio has diagnostic tests for a range of infectious diseases including:
- Dengue fever
- Epstein-Bar virus
- West Nile fever
- Brucellosis
- HHV-7, 7 & 8
- Leptospirosis
- Rickettsial diseases
- Q Fever
- Pertussis
Panbio is recognised as a world leader in tests used in the diagnosis of Flavivirus and other arthropod-borne viruses. The company has a history of market leadership in response to diseases that afflict millions of people and was first to market with diagnostics for dengue fever, Ross River fever and West Nile encephalitis.
www.panbio.com
 
| |
|
|
|
|
|
|
|
|
|
|